The pandemic-induced transition to digital health is, according to the Nuffield Trust, contributing to an “inverse care law” that’s compounding existing health inequalities.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh